CLEU18093 / A041501 / Kristen O'DwyerResearch Question:
What are the side effects of a monoclonal antibody, inotuzumab ozogamicin, and how
well does it work when given with front-line chemotherapy in treating patients with
newly diagnosed B acute lymphoblastic leukemia.
Basic Study Information
Purpose:Location: University of Rochester Medical Center
This partially randomized phase III trial studies the side effects of inotuzumab ozogamicin
and how well it works when given with frontline chemotherapy in treating patients
with newly diagnosed B acute lymphoblastic leukemia. Monoclonal antibodies, such as
inotuzumab ozogamicin, may block cancer growth in different ways by targeting certain
cells. Drugs used in chemotherapy work in different ways to stop the growth of tumor
cells, either by killing the cells, by stopping them from dividing, or by stopping
them from spreading. Giving inotuzumab ozogamicin with chemotherapy may work better
in treating young adults with B acute lymphoblastic leukemia.
Study Reference #: CLEU18093
Lead Researcher (Principal Investigator)
Study Contact InformationStudy Coordinator: Amber Johnson
Additional Study Details
Trial Not Found
The study you are looking for is not active at this time.
Return to Search